Clinical Neuropharmacology, 04/02/2012Goldman JG et al.
Data presented were categorized in 3 groups based on the nature of data presented (radiological, clinical, and immunological data). Both case-control studies and case reports were included, while table classification was in chronological order
B lymphocytes seem to have a fundamental role in multiple sclerosis, acting as sensors, coordinators, and regulators of the immune response.
Furthermore, they are important in activating T cells and they can mediate tissue injury through diverse mechanisms.
Such findings have important therapeutic implications in autoimmune central nervous system diseases in a fashion similar to other autoimmune processes.
The best known monoclonal antibody targeting B cells that has been used as a novel therapy for various autoimmune conditions, as well as multiple sclerosis, is rituximab.
This review summarizes the available data on the role of B cell in multiple sclerosis and further reports on current knowledge on the B-cell–depleting monoclonal antibody rituximab, its mechanism of action, and its efficacy on multiple sclerosis.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.